Identification of the Ligand Binding Site for the Integrin alpha 9beta 1 in the Third Fibronectin Type III Repeat of Tenascin-C*

Yasuyuki YokosakiDagger §, Nariaki Matsuuraparallel , Shigeki Higashiyama**, Isao MurakamiDagger §, Masanobu ObaraDagger Dagger , Michio Yamakido§§, Norikazu ShigetoDagger , John Chen¶¶, and Dean Sheppard¶¶

From the Departments of Dagger  Internal Medicine and § Laboratory Medicine, National Hiroshima Hospital, 513 Jike, Saijoh, Higashi-Hiroshima 739-0041, parallel  Department of Pathology, School of Allied Health Sciences, ** Department of Biochemistry, Faculty of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Dagger Dagger  Department of Developmental Science, Faculty of Science, Hiroshima University, 1-1 Kagamiyama, Saijoh, Higashi-Hiroshima 739-8526, §§ Department of Internal Medicine II, School of Medicine, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima 734-8551, Japan, and the ¶¶ Lung Biology Center, Department of Medicine, University of California, San Francisco, California 94143

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The integrin alpha 9 subunit forms a single heterodimer, alpha 9beta 1 that mediates cell adhesion to a site within the third fibronectin type III repeat of tenascin-C (TNfn3). In contrast to at least 3 other integrins that bind to this region of tenascin-C, alpha 9beta 1 does not recognize the common integrin recognition motif, Arg-Gly-Asp (RGD). In this report, we have used substitution mutagenesis to identify a unique ligand recognition sequence in TNfn3. We introduced mutations substituting alanine for each of the acidic residues in or adjacent to each of the exposed loops predicted from the solved crystal structure. Most of these mutations had little or no effect on adhesion of alpha 9-transfected SW480 colon carcinoma cells, but mutations of either of two acidic residues in the B-C loop region markedly reduced attachment of these cells. In contrast, cells expressing the integrin alpha vbeta 3, previously reported to bind to the RGD sequence in the adjacent F-G loop, attached to all mutant fragments except one in which the RGD site was mutated to RAA. The peptide, AEIDGIEL, based on the sequence of human tenascin-C in this region blocked the binding of alpha 9-transfected cells, but not beta 3-transfected cells to wild type TNfn3. This sequence contains a tripeptide, IDG, homologous to the sequences LDV, IDA, and LDA in fibronectin and IDS in VCAM-1 recognized by the closely related integrin alpha 4beta 1. These findings support the idea that this tripeptide motif serves as a ligand binding site for the alpha 4/alpha 9 subfamily of integrins.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Integrins are cell surface heterodimers that play roles in essential biological processes including development and tissue remodeling (1-4). Ligand binding specificity depends in large part on the specific alpha  and beta  subunit present in each heterodimer. To date, extracellular matrix proteins, cell surface immunoglobulin superfamily molecules, and cadherins have been identified as ligands for integrins. In most cases where the crystal structure of integrin ligands have been solved, the ligand binding site includes at least one acidic residue, generally displayed in an exposed peptide loop (5-7). The first short peptide sequence identified as an integrin recognition sequence was the tripeptide, Arg-Gly-Asp (RGD) (8), initially identified as a cell-recognition sequence in the large extracellular matrix protein, fibronectin (9, 10). Subsequently, this RGD sequence was found to be present in several integrin ligands and to serve as a recognition sequence for several different integrins (11). As the sequences of multiple integrin alpha  subunits were solved, it became clear that these sequences could be divided into 3 subfamilies based on sequence homology (1). One family includes alpha  subunits with a characteristic disulfide-linked cleavage site. A subset of these form heterodimers that recognize RGD-containing ligands. Another includes alpha  subunits that contain an inserted domain close to the N terminus but no cleavage site. These integrins generally do not recognize RGD-containing ligands. Finally, a third family, including only two alpha  subunits, alpha 9 and alpha 4, contains neither an inserted domain nor a disulfide-linked cleavage site (12).

We have previously identified the third fibronectin type III repeat in the extracellular matrix protein tenascin (TNfn3)1 as a ligand for the only known alpha 9-containing integrin, alpha 9beta 1 (13). TNfn3 is also recognized as a ligand by at least three other integrins (14, 15), alpha 8beta 1 (16), alpha vbeta 3 (17), and alpha vbeta 6 (18). The crystal structure of TNfn3 has been solved and consists of a series of seven beta  strands separated by six exposed loops (5). alpha 8beta 1, alpha vbeta 3, and alpha vbeta 6 all bind to the RGD tripeptide contained within the F-G loop. However, unlike each of these integrins, alpha 9beta 1 could mediate adhesion to a fragment in which this site was mutated to RAA, and adhesion was unaffected by RGD peptides, suggesting that the ligand binding site was distinct from this RGD site (13). In the present study, we have used substitution mutagenesis and synthetic peptides to identify this site in an adjacent exposed loop on the same face of tenascin-C as the RGD loop.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell Lines, Antibodies, and Reagents-- Human colon cancer cells (SW480) were stably transfected with either the expression plasmids pcDNAIneoalpha 9, pcDNAIneobeta 3, or the empty vector pcDNAIneo as described previously (19). Cells were maintained in Dulbecco's modified Eagle's medium (BioWhittaker, Walkersville, MD) supplemented with 1 mg/ml neomycin analog, G418 (Life Technologies, Inc.). Anti-alpha 9 monoclonal antibody Y9A2 was generated and characterized in our laboratory as described previously (20). Monoclonal antibody 15/7 that recognizes a ligand binding-dependent epitope on the integrin beta 1 subunit (21) was obtained from Ted Yednock (Athena Neurosciences, South San Francisco). The pGEX plasmids to express glutathione S-transferase fusion proteins including the wild type third fibronectin type III repeat of chicken tenascin-C (TNfn3) or a mutant version in which the RGD site within the F-G loop was mutated to RAA (18) were obtained from Kathryn Crossin (The Scripps Research Institute, La Jolla, CA). Concentrations of recombinant proteins were determined by the Bradford assay (Pierce) using bovine serum albumin as a standard. Peptides were synthesized using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry on a peptide synthesizer (Model 432A, Perkin-Elmer) at Center Laboratory for Research and Education, Osaka University, followed by purification with C18-reversed phase column chromatography.

Cell Adhesion Assay-- As described previously (22), wells of non-tissue culture-treated polystyrene 96-well flat-bottomed microtiter plates (Nunc Inc., Naperville, IL) were coated by incubation with 100 µl of recombinant wild type or mutant tenascin fragment in phosphate-buffered saline at 37 °C for 1 h. For blocking experiments, cells were incubated in the presence or absence of soluble peptide or Y9A2 on ice for 15 min before plating on tenascin fragments. Wells were washed with phosphate-buffered saline, then blocked with 1% bovine serum albumin in Dulbecco's modified Eagle's medium. 50,000 cells were added to each well in 200 µl of serum-free Dulbecco's modified Eagle's medium containing 0.5% bovine serum albumin. Plates were centrifuged at 10 × g for 1 min, then incubated for 1 h at 37 °C in a humidified atmosphere with 5% CO2. Non-adherent cells were removed by centrifugation top side down at 48 × g for 5 min. The attached cells were fixed with 1% formaldehyde, stained with 0.5% crystal violet, and excess dye was washed off with phosphate-buffered saline. The cells were solubilized in 50 µl of 2% Triton X-100 and quantified by measuring the absorbance at 595 nm in a Microplate Reader (Bio-Rad).

Mutagenesis-- Site-directed mutagenesis was performed with the QuickChange site-directed mutagenesis kit (Stratagene, San Diego, CA) as recommended by the manufacturer. Both strands of the expression plasmid were replicated by polymerase chain reaction using Pfu DNA polymerase with two complementary primers designed to introduce the desired mutation. The amplification product was treated with DpnI endonuclease, specific for methylated DNA, to digest the parental DNA template. Then XL-1 blue competent cells were transformed with the polymerase chain reaction-generated nicked plasmid. Plasmids from several isolated colonies were prepared by Wizard mini-prep (Promega, Madison, WI), and inserts were sequenced by ALFred autosequencer (Amersham Pharmacia Biotech, Uppsala, Sweden) with fluorescent-tagged primers flanking the polylinker of the pGEX vector. The verified mutated inserts were subcloned into pGEX vector that had not been amplified by polymerase chain reaction.

Expression of Recombinant TNfn3 Fragments-- Glutathione S-transferase fusion proteins containing either wild type or variant TNfn3 were prepared by bacterial expression with the pGEX plasmids as recommended by the manufacturer. Briefly, competent XL-1 blue cells were transformed by heat shock and grown on ampicillin-containing plates. Individual colonies were picked and propagated in 2 ml of 2× YT medium (16 g/liter tryptone, 10 g/liter yeast extract, and 5 g/liter NaCl) with 100 µg/ml ampicillin at 37 °C overnight. 100 ml of 2× YT medium was inoculated with 1 ml of the bacteria and incubated until A600 reached 0.5-2 at 30 °C, at which time isopropyl-1-thio-beta -galactopyranoside was added to a final concentration of 0.1 mM. Cultures were grown for several more hours, cells were collected and sonicated, and fusion proteins were affinity-purified with glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech). Purity of the product was confirmed by 12.5% SDS-polyacrylamide gel electrophoresis followed by Coomassie Blue staining.

Flow Cytometric Assessment of Peptide Ligation of alpha 9beta 1-- Binding of authentic or scrambled peptides to the ligand binding site of alpha 9beta 1 was assessed by flow cytometry using monoclonal antibody 15/7, which recognizes a ligand binding-dependent epitope on the integrin beta 1 subunit. Mock- or alpha 9-transfected SW480 cells were incubated with the peptides VTDTTAL, AEIDGIEL, or with the scrambled peptide GDLAIEEI in Dulbecco's modified Eagle's medium for 10 min at 4 °C. Cells were then incubated with antibody 15/7 at 15 µg/ml for 20 min at 4 °C at final peptide concentration of 100, 300, or 1,000 µM followed by incubation with secondary phycoerythrin-conjugated goat anti-mouse IgG. Induction of the epitope recognized by 15/7 was then quantified on 5,000 cells with a Becton Dickinson FACSort.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Attachment of alpha 9 Transfectants to Mutant TNfn3-- According to the published crystal structure of TNfn3 (5), there are six extended loops separating seven beta  strands (Fig. 1). The previously characterized RGD sequence is in the F-G loop. Since most integrin binding sites include at least one acidic residue in an extended loop structure, we made a series of alanine substitution mutations encompassing each acidic residue present in or near a predicted loop, including the potential loop at the N terminus of this repeat (Asp-775, Fig. 2). Fig. 2 shows the locations of each of the substitution mutations described in this study. We could identify acidic residues in or adjacent to five loops (all except the loop between the E and F strands). For efficiency, we sometimes made simultaneous mutations in more than one acidic residue.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   The crystal structure of the third fibronectin type III repeat of tenascin-C (adapted from Ref. 5) consisting of six extended loops separating seven beta  strands. F-G loop contains the RGD sequence. The recognition sequence AEIDGIEL for alpha 9beta 1 identified in this study includes portions of the B-C loop and the adjacent C strand.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Alignment of tenascin amino acid sequences of human, chicken, pig, and mouse tenascin-C. The large arrow (right-arrow ) indicates initially mutated series of acidic residues in each loop. Aspartic acid 816, 821, 825 were simultaneously mutated. The remaining 3 mutants generated for further experiments are indicated by small arrows (right-arrow ). Asterisks (*) indicate the RGD sequence. Two-headed arrows under the sequence alignment indicate predicted positions of beta  strands.

We have previously reported that both alpha 9- and beta 3-transfected SW480 cells adhere to wild type TNfn3, whereas mock-transfected cells do not adhere (19). To determine the effects of each mutation on alpha 9beta 1-mediated adhesion, we performed cell adhesion assays on plates coated with wild type TNfn3 or with TNfn3 expressing mutations in one or more loop. To determine the specificity of any decreases in adhesion of alpha 9-transfected cells, we also performed adhesion assays on the same fragments with beta 3-transfected SW480 cells. As previously reported, both alpha 9- and beta 3-transfected cells adhered to wild type TNfn3, but only alpha 9-transfected cells adhered to TNfn3 in which the RGD sequence in the F-G loop was mutated to RAA (Fig. 3). Attachment of alpha 9-transfected cells to wild type TNfn3 was completely blocked by anti-alpha 9 monoclonal antibody Y9A2. Mutations in acidic residues in the N terminus (D775A), the C-C' loop (D812A), or the C-C' and C'-E loops (D816A/D821A/D825A) had no effect on adhesion of either transfectant. However a mutation in the B-C loop (E802A) specifically and markedly reduced attachment of alpha 9-transfected SW480 cells (Fig. 3, panel A). The only other mutation that decreased adhesion of alpha 9-transfected cells was a mutation in the A-B loop (D787A), which reduced adhesion by approximately 40%. Mock-transfected SW480 cells did not adhere to any of the TNfn3 fragments used in this study (data not shown).


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 3.   Attachment of alpha 9- (panel A) and beta 3- (panel B) transfected SW480 cells to wild type TNfn3 or to TNfn3 expressing specific substitution mutations. Numbers of mutated residues are shown on the right. Attachment is expressed as absorbance at 595 nm. Each bar represents the mean (±S.D.) of triplicate wells from a representative experiment.

To examine the role of specific acidic residues in or adjacent to either the B-C or A-B loops, we generated fragments expressing each of 3 additional mutations. Mutations of the aspartic acid residue just proximal to the A-B loop (D784A) or of the most proximal glutamic acid residue in the B-C loop (E800A) had no effect on adhesion. However, mutation of the next glutamic acid residue in the adjacent C beta  strand (E805A) reduced adhesion of alpha 9-transfected cells to the same degree as E802A, either at concentrations of 0.3 µg or at 3 µg/ml, without effect on adhesion of beta 3-transfectants (Fig. 4).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   Attachment of alpha 9- and beta 3- transfected SW480 cells to mutated TNfn3 (panel A, 0.3 µg/ml; panel B, 3 µg/ml) in which an acidic residue in or adjacent to the A-B or B-C loop is mutated to alanine. Numbers of mutated residues are shown on the right. Attachment is expressed as absorbance at 595 nm. Each bar represents the mean (±S.D.) of triplicate wells from a representative experiment.

Effects of Synthetic Peptides on Cell Adhesion to TNfn3-- In an attempt to further determine whether sites in the A-B loop or the B-C loop were critical for alpha 9beta 1-mediated adhesion to TNfn3, we synthesized linear peptides corresponding to the amino acid sequence of each of these loops of human TNfn3 and evaluated the ability of these peptides to inhibit adhesion of either alpha 9-transfected or beta 3-transfected SW480 cells to 3 µg/ml wild type TNfn3 (Fig. 5). We designed these peptides based on the human sequence to increase the likelihood that any effective peptide could serve as a starting point for drug design. The peptide Ala-Glu-Ile-Asp-Gly-Ile-Glu-Leu (AEIDGIEL) based on the B-C loop caused concentration dependent inhibition of adhesion of alpha 9 transfectants with no effect on adhesion of the beta 3-transfected control cells (Fig. 5). In contrast, the peptide Val-Thr-Asp-Thr-Thr-Ala-Leu (VTDTTAL) corresponding to the A-B loop was without effect. In addition, the scrambled peptide GDLAIEEI, based on AEIDGIEL, had no effect on cell adhesion. These data further suggest that the B-C loop is critical to ligand binding.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of synthetic peptides on the attachment of alpha 9- or beta 3-transfected SW480 cells to TNfn3. Cells were incubated with either the peptide AEIDGIEL corresponding to the B-C loop region, the scrambled peptide GDLAIEEI, the peptide VTDTTAL corresponding to A-B loop region, or without peptide (-) before plated onto wells coated with 3 µg/ml TNfn3. Panel A shows attachment of alpha 9-transfected cells in the presence of 3 different concentrations of peptides (100, 300, or 1000 µM). Panel B shows attachment of beta 3-transfected cells in the presence of the highest concentration of peptides (1000 µM). Attachment is expressed as absorbance at 595 nm. Each bar represents the mean (±S.D.) of triplicate wells from a representative experiment.

Effects of Synthetic Peptides on Expression of a Ligand Binding-dependent Epitope on the Integrin beta 1 Subunit-- As further confirmation of the role of the B-C loop sequence in directly interacting with the alpha 9beta 1 integrin, we examined the effects of each peptide on expression of the epitope recognized by the monoclonal antibody 15/7, an antibody that has previously been shown to be made accessible following direct interaction of beta 1-integrins with ligand (21). To determine whether any peptide-induced expression of the 15/7 epitope was specifically due to interaction of peptides with alpha 9beta 1, and not to interaction with other beta 1-integrins expressed on SW480 cells, we compared the effects of each peptide on alpha 9-transfected or mock-transfected cells. The AEIDGIEL peptide, but not the VTDTTAL or scrambled peptides, significantly induced the epitope recognized by antibody 15/7 on alpha 9-transfected cells (Fig. 6). None of the peptides examined affected 15/7 expression of mock-transfected cells, demonstrating that induction of expression was due to specific interaction of the AEIDGIEL peptide with alpha 9beta 1.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of synthetic peptides on expression of a ligand binding-dependent epitope on the integrin beta 1 subunit. Panel A, alpha 9- or mock-transfected SW480 cells were incubated with the synthetic peptides shown at 1000 µM, and 15/7 expression was analyzed by flow cytometry. The expression level of the ligand binding-dependent epitope is compared in the absence of peptides (open histogram) or in the presence of 1000 µM peptide (filled histogram). Panel B, expression level of the ligand binding-dependent epitope on alpha 9-transfected SW480 cells (indicated by the mean fluorescent intensity) is compared for peptide concentrations of 0, 100, 300, or 1000 µM. Panel C, expression level of the ligand binding-dependent epitope on mock-transfected SW480 cells.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Previous work identified tenascin-C as a ligand for the integrin alpha 9beta 1 and localized the binding site to TNfn3 (13). In the present study, we have used substitution mutagenesis and synthetic peptides to map the ligand binding site within this repeat in more detail. The dramatic reduction of adhesion of alpha 9-transfected, but not beta 3-transfected cells to mutant fragments in which either the second or third acidic residue in the B-C loop region was replaced with alanine identify this region as critical for ligand binding. The effect of a peptide based on this region, AEIDGIEL, but not of a corresponding scrambled peptide in inhibiting adhesion of alpha 9-transfected cells to wild type TNfn3, and specific induction of a ligand binding-dependent epitope on the beta 1 subunit by the same peptide, provide further evidence that this region includes the ligand binding site.

One other mutation, D787A, involving an acidic residue in the A-B loop also decreased adhesion of alpha 9-transfected SW480 cells. On the basis of this result, we cannot exclude a role for this region in binding to alpha 9beta 1. However, several pieces of evidence suggest that the A-B loop is unlikely to be the principal site of interaction with this integrin. First the degree of inhibition caused by this mutation was much less than that caused by mutations in the B-C loop. This partial inhibition was not due to a contribution by other adjacent acidic residues to alpha 9beta 1 adhesion, since mutation of the only adjacent acidic residue had no effect on adhesion. Furthermore, a peptide corresponding to this region, VTDTTAL, had no effect on adhesion and did not induce the ligand-dependent epitope on the beta 1 subunit. It is thus likely that the D787A mutation inhibited adhesion by altering the conformation of a critical region of the B-C loop on the opposite face of TNfn3.

Several ligand binding sites for integrins have now been mapped within fibronectin type III repeats and immunoglobulin domains (23-27). Most of these sites have been mapped to short linear sequences involving exposed peptide loops. In every case these sequences have included a critical acidic residue. Many of these sites include the classic integrin recognition motif, RGD, but binding to RGD sites is largely restricted to integrins that contain the closely related alpha  subunits (alpha 5, alpha 8, alpha IIb, and alpha v) containing a disulfide-linked cleavage site. Based on its amino acid sequence, alpha 9 is most similar to alpha 4 (28). Recognition sites for the integrin alpha 4beta 1 in the ligands fibronectin and VCAM-1 have been extensively investigated. In fibronectin, 3 sites have been identified: LDV (23) in the alternatively spliced IIICS type III repeat, IDAP (24) in C-terminal heparin binding domain, HepII, and KLDAPT (25) in the fifth type III repeat. In VCAM-1, the binding sequence for alpha 4beta 1 is IDSP (26, 27). All of these recognition sequences contain a homologous tripeptide composed of a leucine or isoleucine followed by an acidic residue, followed by a neutral amino acid with a small side chain. The sequence we identified in this study, AEIDGIEL, contains a homologous tripeptide, IDG. Recognition of the importance of this motif could facilitate the identification of other integrin ligands.

The synthetic peptide used in this study, AEIDGIEL, specifically inhibited alpha 9beta 1-mediated cell adhesion. The potency of this peptide was quite low, however, requiring a concentration of 1000 µM to achieve approximately 50% inhibition. This particular peptide is thus not likely to itself be useful as a reagent to examine the functional significance of alpha 9beta 1 in vivo. Nonetheless, since the crystal structure of TNfn3 has been solved, this peptide and the known structure of the B-C loop could serve as starting points for the development of drugs (8, 29) specifically targeting this integrin.

    ACKNOWLEDGEMENT

We thank Dr. Kathryn L. Crossin (The Scripps Research Institute) for the pGEX plasmid to express TNfn3 and TNfn3RAA, and Dr. Ted Yednock (Athena Neuroscience) for supplying antibody 15/7.

    FOOTNOTES

* This work was supported in part by Research Grant for Cardiovascular Diseases 8C-1, Grants-in-aid for Cancer Research 7-16 and 9-39 from the Ministry of Health and Welfare (to Y. Y.), by a grant from the Tsuchiya Memorial Foundation for Medical Research (to Y. Y.) and by National Institutes of Health Grant HL/AI33259 (to D. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Internal Medicine, National Hiroshima Hospital, 513 Jike, Saijoh HigashiHiroshima 739-0041, Japan. Tel.: 81-824-23-2176; Fax: 81-824-22-4675; E-mail: yokosaki{at}hirosima.hosp.go.jp.

1 The abbreviation used is: TNfn3, third fibronectin type III repeat.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Hynes, R. O. (1992) Cell 69, 11-25[Medline] [Order article via Infotrieve]
  2. Clark, E., and Brugge, J. (1995) Science 268, 233-239[Medline] [Order article via Infotrieve]
  3. Sheppard, D. (1996) Bioessays 18, 655-660[Medline] [Order article via Infotrieve]
  4. Sheppard, D., and Yokosaki, Y. (1996) Chest 109, 29S-33S[Free Full Text]
  5. Leahy, D. J., Hendrickson, W. A., Aukhil, I., and Erickson, H. P. (1992) Science 258, 987-991[Medline] [Order article via Infotrieve]
  6. Jones, E., Harlos, K., Bottomley, M., Robinson, R., Driscoll, P., Edwards, R., Clements, J., Dudgeon, T., and Stuart, D. (1995) Nature 373, 539-544[CrossRef][Medline] [Order article via Infotrieve]
  7. Leahy, D., Aukhil, I., and Erickson, H. (1996) Cell 84, 155-164[Medline] [Order article via Infotrieve]
  8. Ruoslahti, E. (1996) Ann. Rev. Cell Dev. Biol. 12, 697-715[CrossRef][Medline] [Order article via Infotrieve]
  9. Pierschbacher, M. D., and Ruoslahti, E. (1984) Nature 309, 30-33[Medline] [Order article via Infotrieve]
  10. Pytela, R., Pierschbacher, M. D., and Ruoslahti, E. (1985) Cell 40, 191-198[Medline] [Order article via Infotrieve]
  11. Hynes, R. O. (1987) Cell 48, 549-554[Medline] [Order article via Infotrieve]
  12. Palmer, E. L., Ruegg, C., Ferrando, R., Pytela, R., and Sheppard, D. (1993) J. Cell Biol. 123, 1289-1297[Abstract]
  13. Yokosaki, Y., Palmer, E. L., Prieto, A. L., Crossin, K. L., Bourdon, M. A., Pytela, R., and Sheppard, D. (1994) J. Biol. Chem. 269, 26691-26696[Abstract/Free Full Text]
  14. Yokosaki, Y., and Sheppard, D. (1995) Trends Glycosci. Glycotechnol. 7, 417-427
  15. Chiquet-Ehrismann, R. (1995) Curr. Opin. Cell Biol. 7, 715-719[CrossRef][Medline] [Order article via Infotrieve]
  16. Schnapp, L. M., Hatch, N., Ramos, D. M., Klimanskaya, I. V., Sheppard, D., and Pytela, R. (1995) J. Biol. Chemi. 270, 23196-23202[Abstract/Free Full Text]
  17. Joshi, P., Chung, C.-Y., Aukhil, I., and Erickson, H. P. (1993) J. Cell Sci. 106, 389-400[Abstract/Free Full Text]
  18. Prieto, A. L., Edelman, G. M., and Crossin, K. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10154-10158[Abstract]
  19. Yokosaki, Y., Monis, H., Chen, J., and Sheppard, D. (1996) J. Biol. Chem. 271, 24144-24150[Abstract/Free Full Text]
  20. Wang, A., Yokosaki, Y., Ferrand, R., Balmas, J., and Sheppard, D. (1996) Am. J. Respir. Cell Mol. Biol. 15, 664-672[Abstract]
  21. Yednock, T. A., Cannon, C., Vandevert, C., Goldbach, E. G., Shaw, G., Ellis, D. K., Liaw, C., Fritz, L. C., and Tanner, L. I. (1995) J. Biol. Chem. 270, 28740-28750[Abstract/Free Full Text]
  22. Weinacker, A., Chen, A., Agrez, M., Cone, R. I., Nishimura, S., Wayner, E., Pytela, R., and Sheppard, D. (1994) J. Biol. Chem. 269, 6940-6948[Abstract/Free Full Text]
  23. Komoriya, A., Green, L. J., Mervic, M., Yamada, S. S., Yamada, K. M., and Humphries, M. J. (1991) J. Biol. Chem. 266, 15075-15079[Abstract/Free Full Text]
  24. Mould, A., and Humphries, M. (1991) EMBO J. 10, 4089-4095[Abstract]
  25. Moyano, J. V., Carnemolla, B., Dominguez-Jimenez, C., Garcia-Gila, M., Albar, J. P., Sanchez-Aparicio, P., Leprini, A., Querze, G., Zardi, L., and Garcia-Pardo, A. (1997) J. Biol. Chem. 272, 24832-24836[Abstract/Free Full Text]
  26. Clements, J. M., Newham, P., Shepherd, M., Gilbert, R., Dudgeon, T. J., Needham, L. A., Edwards, R. M., Berry, L., Brass, A., and Humphries, M. J. (1994) J. Cell Sci. 107, 2127-2135[Abstract/Free Full Text]
  27. Osborn, L., Vassallo, C, Browning, B., Tizard, R., Haskard, D., Benjamin, C., Dougas, I., and Kirchhausen, T. (1994) J. Cell Biol. 124, 601-608[Abstract]
  28. Takada, Y., Elices, M. J., Crouse, C., and Hemler, M. E. (1989) EMBO J. 8, 1361-1368[Abstract]
  29. Stadel, J., Nichols, A., Bertolini, D., and Samanen, J. (1994) in Integrin: Molecular and Biological Responses to the Extracellular Matrix (Cherish, D., and Mecham, R., eds), pp. 237-271, Academic Press, San Diego


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.